Dataset - CKAN

A new methodology for phase II trials to improve therapeutic targeting in onc...

The majority of phase III clinical trials, despite being conducted after promising phase II trials, are "negative," with the new therapy determined in the end to be...
- HTML

You can also access this registry using the API (see API Docs).